Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.

Pyrilutamide, a potentially effective hair loss treatment; other topical treatments like RU58841 and CB-03-01 that may have fewer side effects than Pyrilutamide; and the Phase 3 clinical trials of Pyrilutamide, which is likely to be approved by the FDA soon.

The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.

The conversation discusses the legitimacy of purchasing Pyrilutamide (KX-826) for hair loss treatment. Users mention using Minoxidil and express interest in waiting for phase 3 trials for safety and efficacy confirmation.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The user has been using minoxidil daily, finasteride three times a week, and ketoconazole 1-3 times a week for a year to treat hair loss, resulting in noticeable hair regrowth at the hairline and temples, with minor side effects like itching and dandruff. They started with minoxidil a month before the other treatments and experienced an initial shedding phase for about six weeks.

A 19-year-old experiencing severe hair loss since 16 is using a treatment regimen of 5% minoxidil, 0.1% finasteride topical solution, 3% procapil hair serum, and 0.5 mg dutasteride daily. They are concerned about the effectiveness and potential shedding phase, with advice suggesting noticeable changes in 6 to 8 months.

The user experienced hair loss improvement using finasteride, minoxidil, Nizoral, and dermastamping over two years, progressing from a diffuse NW3-3.5 to a thicker NW2.5. They advise starting treatment early, enduring shedding phases, and avoiding excessive time on forums.

The user experienced significant hair regrowth in three months using a capsule containing minoxidil and finasteride. They reported no major side effects and plan to continue the treatment until their late 20s.

Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

An 18-year-old shared his 3-month hair regrowth progress using Kirkland 5% topical minoxidil and a dermaroller, achieving a better hairline without finasteride. He plans to switch from liquid to foam minoxidil for easier styling and is cautious about starting finasteride due to potential hormonal effects.

Topical dutasteride 0.05% is more effective for hair growth than oral finasteride 1mg, with minimal DHT reduction. The formulation uses castor oil and MCTs for better absorption but is not widely available until 2028.

A 24-year-old male doctor shares his 3-month progress using 0.5 mg oral finasteride and 5% topical minoxidil daily, noting some hair regrowth and incorporating microneedling. He prefers a "less is more" approach initially and discusses the potential benefits of oral minoxidil.

A 21-year-old male has been using 1mg finasteride, 2ml minoxidil, and supplements for almost 3 months but is still experiencing hair loss. Responses advise patience and consistency, noting that initial shedding is common.

A 26-year-old male shared his 3-month progress using Minoxidil and finasteride daily, microneedling weekly, and occasional vitamin D3. A commenter praised his impressive results.

A 29-year-old man shows 3 months of hair regrowth using minoxidil 5%, oral dutasteride 0.5mg every other day, and occasional microneedling after overcoming fears about finasteride side effects. He is optimistic about further improvement.

A user shared their 3-month progress using finasteride, minoxidil, Pura D'or Shampoo, Nizoral, and vitamins. They reported improvement in their hairline and increased confidence, with hopes for further progress in the crown area.

The user started using topical minoxidil 5% and ketoconazole shampoo for hair loss, noticing minimal progress after three months, with fine hairs appearing. They experienced a setback when reducing the application to once a day but resumed twice daily applications.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

A 36-year-old has been using 5% Minoxidil for 3.5 months and is considering adding microneedling and PRP. Another user suggests adding finasteride and microneedling for better results.

The user has been using Minoxidil for 4 years and recently added a derma pen and Trinov to their regimen, but results are inconclusive after 3 months. Some users suggest Trinov is ineffective and recommend alternatives like Clascoterone (Breezula) for better results.

The user has been using minoxidil for almost 6 months and finasteride for almost 4 months, experiencing significant shedding and minimal stabilization. They are considering switching to dutasteride if no improvements are seen and are advised to be patient, as results may take up to 2 years.

The user shared progress on hair regrowth using finasteride, minoxidil, dermastamp, Nizoral shampoo, and scalp massage, showing significant improvement in three months. The user reported no side effects and asked if early regrowth is normal.

The user has been using 1mg finasteride and 2.5mg oral minoxidil for three months, noticing new blonde hairs but experiencing ongoing shedding. They also use GHK-Cu, which has improved skin but not hair.